Enterprise Value
3.203M
Cash
77.61M
Avg Qtr Burn
-20.29M
Short % of Float
7.03%
Insider Ownership
28.68%
Institutional Own.
40.82%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-0508 (HER2) + pembrolizumab Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CT-0525 Details Cancer, Solid tumor/s | Phase 1 Initiation | |
Vicineum™ Details Bladder cancer, Cancer | Failed Discontinued | |
Vicineum™ Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
CT-0508 (HER2) Details Solid tumor/s, Cancer | Failed Discontinued |